“Watch the video shared by the Canadian Pulmonary Fibrosis Foundation to understand what is like to live with IPF through the eyes of patients and their families.” Learn more about Esbriet that addresses Idiopathic Pulmonary Fibrosis: https://bit.ly/Esbriet…
What It’s Like To Live With IPF?
The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…
Boehringer Ingelheim Pharmaceuticals, Inc., recently announced data on the first 49 patients participating in the IPF-PRO (Idiopathic Pulmonary Fibrosis – PROspective Outcomes) Registry, better characterizing the features of patients with IPF when they are diagnosed with the disease. The data was presented at the American College of…
Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both the efficacy and safety…
Reata Pharmaceuticals, a clinical-stage biopharmaceutical company, recently presented results from the LARIAT trial investigating the drug bardoxolone methyl in patients with pulmonary arterial hypertension (PAH). The study entitled “Bardoxolone Methyl Evaluation in Patients with Pulmonary Arterial Hypertension (PAH)” was presented in the 2015 American College…
One of the country’s leading organizations dedicated to finding a cure for pulmonary fibrosis (PF), the Pulmonary Fibrosis Foundation (PFF), recently revealed the recipients of this year’s Established Investigator and Junior Investigator Awards. These prestigious research grants are directly supported by the Foundation’s Research Fund to Cure Pulmonary Fibrosis, and given only to…
In a recent study entitled “Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis,” a team of researchers investigated the differences in gene expression in fibroblast foci in patients with idiopathic pulmonary fibrosis (IPF). They found that the expression of a particular gene, USP13,…
The program for the upcoming PFF Summit 2015: From Bench to Bedside has been announced by the Pulmonary Fibrosis Foundation (PFF), the organizer of the event. The third biennial international healthcare conference on pulmonary fibrosis (PF) will take place between November 12 and 14 in Washington, D.C., and will…
ProMetic Life Sciences, Inc., a biopharmaceutical company focused on plasma-derived therapeutics and small-molecule drug development, recently announced that its product PBI-4050 for the treatment of idiopathic pulmonary fibrosis (IPF) has been granted orphan drug designation status by the European Commission. IPF is a progressive fatal lung disease of unknown…
A new study published in the journal Respiratory Research revealed that an enzyme called matrix metalloproteinase 10 may be a suitable novel biomarker for idiopathic pulmonary fibrosis (IPF). The study was led by researchers at the Kyoto University in Japan and is entitled “Matrix metalloproteinase-10:…
